MvPI and the Indian Pharmacopoeia Commission: Adverse Event Reporting

1. Key takeaways

The Materiovigilance Programme of India (MvPI) is India’s national medical device adverse event reporting system. It was approved and launched by the Ministry of Health and Family Welfare in 2015, and the Indian Pharmacopoeia Commission (IPC) has served as the National Coordination Centre (NCC) since 2018. The programme collects, compiles and analyses voluntarily reported medical device adverse events (MDAEs) and makes recommendations to the regulatory authorities. For licence holders, the programme matters in two ways at once: it is the practical channel through which adverse event information reaches the Indian system, and it operates alongside — not instead of — the statutory 15-day notification duties in the Medical Devices Rules, 2017.

• MvPI was approved and launched in 2015 by the Ministry of Health and Family Welfare to monitor and help assure the safety of medical devices used in the Indian population.
• The IPC has acted as the National Coordination Centre since 2018.
• Reports are collected through recognised medical colleges, hospitals and related institutions designated as Medical Device Adverse Event Monitoring Centres (MDMCs), each with coordinators or deputy coordinators drawn from clinicians, pharmacologists, biomedical engineers or other healthcare professionals.
• For MAHs, manufacturers, importers and distributors, serious events must be reported to the regulatory authority and the NCC within 15 calendar days; for healthcare professionals, serious events carry 15 calendar days and non-serious events 30 calendar days.
• The minimum information criteria require five elements: a reportable adverse event, an identifiable patient, a reporter, product exposure, and the device category or model.

2. Legal basis

The MvPI is not itself a rule in the Medical Devices Rules, 2017; it is a national programme built on official and industry documentation, and its operating details come from programme guidance. That distinction shapes how its requirements should be read: the timelines below are presented as an industry-compiled practical estimate of MvPI guidance rather than as statutory text, while the programme’s structure and mandate rest on its official establishment documents.

The design is deliberately layered. The NCC sits at the centre, the MDMCs feed reports in from the clinical front line, and the marketing authorisation holders, manufacturers, importers and distributors report from the industry side. Both streams converge on the same programme, which is what allows the MvPI to analyse signals from more than one direction.

3. Expert insights

Insight one: MvPI and CDSCO are complementary lines, not alternatives. The MvPI collects and analyses signals; the CDSCO takes regulatory decisions on the evidence. Reporting into the MvPI does not discharge the statutory duty to notify the licensing authority under Rule 26(ii), with its 15-day window. A company that files the MvPI form and considers the matter closed has, in the eyes of the rules, missed the separate obligation running to the authority. The two channels must be treated as parallel tracks that the same internal event record feeds simultaneously.

Insight two: the hospital’s reporting duty is independent. Healthcare institutions report directly to the MvPI through their MDMCs, in parallel with the company-side report. This means the same event can enter the system from two directions. A company cannot rely on the assumption that the customer will report the event; the hospital may do so, and the regulator will then hold the company’s silence against it. The practical consequence is that every complaint received from a clinical user must be treated as a potential trigger for the company’s own reporting clock, regardless of what the institution does.

Insight three: the minimum information criteria are the qualification line for a report. The MvPI requires five elements to be present: a reportable event, an identifiable patient, a reporter, product exposure, and the device category or model. If any one of the five is missing, the report struggles to support a root cause analysis. This is why the quality of complaint intake at the company determines the quality of the report at the regulator: fields captured cleanly at first contact become fields that carry weight in the analysis, while fields reconstructed weeks later rarely do.

Insight four: cardiovascular devices are a priority category for the MvPI. Drug-eluting stents, heart valves, bioresorbable vascular scaffold systems, thrombectomy sets and cardiac pacemakers, among others, are classified as Class D devices in India and sit at the top of the MvPI’s monitoring priorities. Manufacturers in this space should assume a correspondingly higher level of scrutiny of their adverse event records and should align their internal timelines to the strictest reading of the guidance.

4. Practical recommendations

• Embed MvPI reporting into the routine vigilance workflow as a standing process, not as an ad hoc action triggered case by case.
• Map the fields of the MvPI reporting form to the fields of the company’s existing global vigilance system, once, in a documented mapping table.
• After the mapping is in place, configure the global system so that when an India-relevant event is received, a first draft in MvPI format is generated automatically from the mapping.
• Check every report against the five minimum information elements — event, patient, reporter, exposure and model — before submission, because a missing element weakens the analysis downstream.
• Record the 15-calendar-day deadline for serious events and the 30-calendar-day deadline for non-serious events from healthcare professionals in the compliance calendar, and treat the dual reporting lines to the MvPI and to the licensing authority as one coordinated process.

This mapping approach delivers two benefits at once: it protects the 15-day timeline, because the draft no longer depends on manual re-entry, and it prevents the information distortion that hand-copying between systems introduces. The company’s global record and its Indian report stay identical by construction rather than by correction.

5. Verification checklist

• ☐ It has been confirmed internally that the MvPI and CDSCO reporting lines run in parallel
• ☐ Reporting fields have been mapped to the company’s existing global vigilance system
• ☐ The five minimum information elements — event, patient, reporter, exposure, model — are complete on every report
• ☐ Independent hospital-side reporting through MDMCs has been taken into account
• ☐ The 15-day (serious) and 30-day (non-serious) deadlines have been entered in the compliance register

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com